M&A / Deals Teva makes its first M&A play in years, buying Emalex PharmaphorumTeva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m. Read full story Post navigation Previous: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolioNext: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
